GLP-1 based therapies and disease course of inflammatory bowel disease

BACKGROUND: The disease course of inflammatory bowel disease (IBD) following treatment with glucagon-like peptide (GLP)-1 based therapies is unclear. The aim of this study was to examine the disease course of IBD in patients treated with GLP-1 based therapies compared with treatment with other antid...

Descripción completa

Detalles Bibliográficos
Autores principales: Villumsen, Marie, Schelde, Astrid Blicher, Jimenez-Solem, Espen, Jess, Tine, Allin, Kristine Højgaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343256/
https://www.ncbi.nlm.nih.gov/pubmed/34386751
http://dx.doi.org/10.1016/j.eclinm.2021.100979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343256/
https://www.ncbi.nlm.nih.gov/pubmed/34386751
http://dx.doi.org/10.1016/j.eclinm.2021.100979

Ejemplares similares